<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099423</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-30073</org_study_id>
    <secondary_id>EU-21022</secondary_id>
    <secondary_id>PFIZER-EORTC-30073</secondary_id>
    <nct_id>NCT01099423</nct_id>
  </id_info>
  <brief_title>Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <acronym>SURTIME</acronym>
  <official_title>Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wales Cancer Trials Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Urologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib&#xD;
      malate before surgery may make the tumor smaller and reduce the amount of normal tissue that&#xD;
      needs to be removed. Giving sunitinib malate after surgery may kill any tumor cells that&#xD;
      remain after surgery. It is not yet known whether undergoing immediate surgery or surgery&#xD;
      after sunitinib malate is more effective in treating patients with metastatic kidney cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying immediate surgery to see how well it&#xD;
      works compared with surgery after sunitinib malate in treating patients with metastatic&#xD;
      kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine if immediate versus deferred nephrectomy has an effect on disease control&#xD;
           in patients with resectable, synchronous, metastatic renal cell carcinoma treated with&#xD;
           sunitinib malate.&#xD;
&#xD;
        -  To identify potential response criteria based on histopathology and molecular research&#xD;
           on tumor tissue.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to WHO performance&#xD;
      status (0 vs 1), number of metastatic sites (1 vs 2 or more), and institution. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (immediate nephrectomy): Patients undergo cytoreductive nephrectomy. Beginning 4&#xD;
           weeks after surgery, patients receive oral sunitinib malate once daily on days 1-28.&#xD;
           Treatment with sunitinib malate repeats every 6 weeks for 4 courses in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (deferred nephrectomy): Patients receive oral sunitinib malate once daily on days&#xD;
           1-28. Treatment repeats every 6 weeks for 3 courses in the absence of disease&#xD;
           progression or unacceptable toxicity. About 1 day after completion of sunitinib malate,&#xD;
           patients undergo cytoreductive nephrectomy. Patients then receive oral sunitinib malate&#xD;
           once daily on days 1-28. Treatment repeats every 6 weeks for 2 courses in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Some patients undergo tumor tissue collection at baseline and at time of surgery to assess&#xD;
      possible differences in gene expression. Patients also undergo blood sample collection&#xD;
      periodically to evaluate the potential impact of serum proteins on the clinical outcome.&#xD;
      Samples are then stored for future studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response to treatment in the deferred nephrectomy arm including the proportion of patients who become unresectable</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of nephrectomy on early progression in both arms</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Immediate nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery followed by Sunitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred nephrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib (3 cycles) followed by surgery followed by Sunitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>timing of surgery</intervention_name>
    <arm_group_label>Deferred nephrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>Deferred nephrectomy</arm_group_label>
    <arm_group_label>Immediate nephrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biologic sample preservation procedure</intervention_name>
    <arm_group_label>Deferred nephrectomy</arm_group_label>
    <arm_group_label>Immediate nephrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Deferred nephrectomy</arm_group_label>
    <arm_group_label>Immediate nephrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Immediate nephrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed renal cell cancer (RCC)&#xD;
&#xD;
               -  Clear-cell subtype with a resectable asymptomatic in situ primary&#xD;
&#xD;
                    -  Asymptomatic primary is defined as the absence of symptoms* which can be&#xD;
                       exclusively assigned to the primary tumor such as flank pain and/or gross&#xD;
                       hematuria necessitating blood transfusion NOTE: *Para-neoplastic symptoms&#xD;
                       cannot be assigned to the primary tumor alone in metastatic disease, they&#xD;
                       are not included in this definition.&#xD;
&#xD;
                    -  No symptomatic primary tumor necessitating nephrectomy&#xD;
&#xD;
          -  Resectable primary tumor&#xD;
&#xD;
               -  Bulky locoregional lymph node metastases larger than the primary tumor allowed&#xD;
                  provided resectability of the lymph nodes is surgically feasible&#xD;
&#xD;
          -  Metastatic RCC&#xD;
&#xD;
               -  Distant metastases are not completely resectable at the time of surgery or during&#xD;
                  an additional intervention&#xD;
&#xD;
               -  No multiple distant lesions at one site&#xD;
&#xD;
               -  No bone-only metastases&#xD;
&#xD;
          -  Measurable disease, both primary and metastatic, according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Planning to receive sunitinib malate as background therapy&#xD;
&#xD;
          -  Patients with &gt; 3 of the following surgical risk factors are not eligible:&#xD;
&#xD;
               -  Serum albumin CTCAE v 4.0 grade 2 or worse&#xD;
&#xD;
               -  Serum LDH &gt; 1.5 times upper limit of normal&#xD;
&#xD;
               -  Liver metastases&#xD;
&#xD;
               -  Symptoms at presentation due to metastases&#xD;
&#xD;
               -  Retroperitoneal lymph node involvement&#xD;
&#xD;
               -  Supra-diaphragmatic lymph node involvement&#xD;
&#xD;
               -  Clinical stage T3 or T4 disease&#xD;
&#xD;
          -  No clinical signs of CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  WBC &gt; 3.0 x 10^9/L&#xD;
&#xD;
          -  Platelet count &gt; 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt; 10.0 g/dL&#xD;
&#xD;
          -  PT/PTT or INR ≤ 1.2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  ALT ≤ 2.5 times ULN (≤ 5 times ULN if liver lesions)&#xD;
&#xD;
          -  Serum calcium &lt; 10.0 mg/dL&#xD;
&#xD;
          -  Calculated or measured creatinine clearance &gt; 30 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception 2 weeks before and during study&#xD;
             treatment&#xD;
&#xD;
          -  LVEF normal by MUGA scan or ECHO&#xD;
&#xD;
          -  12-lead ECG normal&#xD;
&#xD;
          -  No serious cardiac illness (myocardial infarction and/or treatable or untreatable&#xD;
             angina pectoris not responding to treatment) within the past 12 months&#xD;
&#xD;
          -  No uncontrolled, high BP (≥ 150/100 mm Hg) despite optimal medical therapy&#xD;
&#xD;
          -  No current pulmonary disease&#xD;
&#xD;
          -  No active or uncontrolled infections, serious illnesses, malabsorption syndrome, or&#xD;
             medical conditions, including patients with a history of chronic alcohol abuse,&#xD;
             hepatitis, HIV, and/or cirrhosis&#xD;
&#xD;
          -  No malignancies within the past 5 years except renal cell carcinoma, basal or squamous&#xD;
             cell carcinoma of the skin, carcinoma in situ of the cervix, resected incidental&#xD;
             prostate cancer staged pT2 with Gleason Score ≤ 6 and postoperative PSA &lt; 0.5 ng/mL,&#xD;
             or patients with any history of malignancies who are disease-free for more than 5&#xD;
             years&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior local radiotherapy for bone lesions allowed&#xD;
&#xD;
          -  No prior systemic therapy for metastatic RCC&#xD;
&#xD;
          -  No prior partial or total nephrectomy&#xD;
&#xD;
          -  No concurrent systemic corticosteroid and/or other immunosuppressive systemic&#xD;
             therapies&#xD;
&#xD;
          -  No concurrent radiotherapy, except palliative radiotherapy&#xD;
&#xD;
          -  No concurrent participation in another clinical trial testing treatments for any&#xD;
             disease including renal cell carcinoma&#xD;
&#xD;
          -  No other concurrent investigational or systemic therapy for metastatic RCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Bex</last_name>
    <role>Study Chair</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John B.A.G. Haanen</last_name>
    <role>Study Chair</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St. Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Hospital</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninghe - Campus Loofstraat</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan - Campus Sint-Jozef</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Pavillon Saint-Luc</name>
      <address>
        <city>Montreal,</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital, The Integrated Cancer Program- General Campus</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Oci / Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamond Health Care Centre</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Camillo Forlanini Hospitals</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum - Universiteit van Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum - Academisch Ziekenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James'S University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and The London NHS Trust - St. Bartholomew'S Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust - Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singelton Hospital</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2010</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

